Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses

a technology of chimeric antigen receptor and target protein, which is applied in the direction of immunoglobulins, peptides, drugs against animals/humans, etc., can solve the problems of impaired autoregulation, severe cytokine release syndrome, and inability to achieve significant side effects, etc., to achieve high transfection efficiency, improve the effect of introduction efficiency and high transfection efficiency

Pending Publication Date: 2021-09-30
DANA FARBER CANCER INST INC
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about using a special type of immune cell, called CAR T cells, to treat cancer. These cells can be introduced into a patient and then a chemical compound can be given to them to help them attack the cancer cells. The treatment has been tested in patients with several types of cancer, including kidney, cervical, bone, brain, and others. The patent also mentions that the treatment can be used against leukemia and lymphoma, which are also types of cancer.

Problems solved by technology

CAR T-cell therapy is not, however, without significant side effects.
Severe cytokine release syndrome is described as a cytokine storm, and can be fatal.
Catabolism of the nucleic acids to uric acid leads to hyperuricemia; the marked increase in uric acid excretion can result in the precipitation of uric acid in the renal tubules and renal vasoconstriction, impaired autoregulation, decreased renal flow, oxidation, and inflammation, resulting in acute kidney injury.
Hyperphosphatemia with calcium phosphate deposition in the renal tubules can also cause acute kidney injury.
High concentrations of both uric acid and phosphate potentiate the risk of acute kidney injury because uric acid precipitates more readily in the presence of calcium phosphate and vice versa that results in hyperkalemia, hyperphosphatemia, hypocalcemia, remia, and acute renal failure.
This approach is limited by the delayed kinetics of response and the potential for immunogenic reaction to HSV.
While expression of “suicide” genes provides a mechanism to reverse the unwanted toxicities, both approaches are considered irreversible, effectively limiting any further therapeutic benefit to the patient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
  • Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
  • Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses

Examples

Experimental program
Comparison scheme
Effect test

example 1 ′

Example 1′: Synthesis of IMiD Derivatives and Degrons

[0742]

General Procedure I: IMiD Condensation

2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (D-1)

[0743]In a 20 mL glass vial, a mixture of 3-hydroxyphthalic anhydride (500 mg, 3.05 mmol, 1 equiv), potassium acetate (927 mg, 9.44 mmol, 3.1 equiv) and 3-aminopiperidine-2,6-dione hydrochloride (552 mg, 3.35 mmol, 1.1 equiv) in acetic acid (10.2 mL, 0.3 M) was heated to 90° C. overnight. The black reaction mixture was cooled to room temperature and diluted to 20 mL with water, and subsequently cooled on ice for 30 min. The resulting slurry was transferred to a 50 mL Falcon tube, which was centrifuged at 3500 rpm for 5 min. The supernatant was discarded and the black solid was transferred to a 250 mL RBF with methanol and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (CH2Cl2:MeOH (9:1)) to afford the title compound as a white solid (619 mg, 74%). 1H NMR (400 MHz, DMSO-d6) δ 11.0...

example 22

of dBET22

[0870]

[0871]A 0.1 M solution of N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (247 microliters, 0.0247 mmol, 1 eq) was added to (S)-4-(4-chlorophenyl)-6-(2-methoxy-2-oxoethyl)-3,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-2-carboxylic acid (10.98 mg, 0.0247 mmol, 1 eq) at room temperature. DIPEA (12.9 microliters, 0.0740 mmol, 3 eq) and HATU (9.4 mg, 0.0247 mmol, 1 eq) were added. The mixture was then stirred for 21 hours, then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH / DCM, 25 minute gradient) gave the desired product as a white solid (9.79 mg, 0.0118 mmol, 48%). 1H NMR (400 MHz, Methanol-d4) δ 7.80 (dd, J=8.4, 7.4 Hz, 1H), 7.51 (dd, J=7.1, 1.5 Hz, 1H), 7.48-7.34 (m, 5H), 5.11 (d...

example 23

of dBET23

[0872]

[0873]A 0.1 M solution of N-(8-aminooctyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide trifluoroacetate in DMF (220 microliters, 0.0220 mmol, 1 eq) was added to (S)-4-(4-chlorophenyl)-6-(2-methoxy-2-oxoethyl)-3,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-2-carboxylic acid (9.87 mg, 0.0220 mmol, 1 eq) at room temperature. DIPEA (11.5 microliters, 0.0660 mmol, 3 eq) and HATU (8.4 mg, 0.0220 mmol, 1 eq) were added. The mixture was then stirred for 21 hours, then diluted with EtOAc and washed with saturated sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (ISCO, 4 g silica column, 0-10% MeOH / DCM, 25 minute gradient) gave the desired product as a white solid (8.84 mg, 0.00998 mmol, 45%). 1H NMR (400 MHz, Methanol-d4) δ 7.81 (dd, J=8.4, 7.4 Hz, 1H), 7.53 (d, J=7.3 Hz, 1H), 7.50-7.39 (m, 5H), 5.12 (dd, J=1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

Description

RELATED APPLICATIONS[0001]This application is a U.S. Divisional Application of U.S. application Ser. No. 15 / 889,963, filed Feb. 6, 2018, which is a continuation of International Application No. PCT / US2016 / 046088, filed Aug. 8, 2016, which claims the benefit of provisional U.S. Application No. 62 / 202,076, filed Aug. 6, 2015, provisional U.S. Application No. 62 / 323,591, filed Apr. 15, 2016, and provisional U.S. Application No. 62 / 323,575, filed Apr. 15, 2016. The entirety of each of these applications is hereby incorporated by reference.GOVERNMENT LICENSE RIGHTS[0002]This invention was made with government support under grant numbers R01 CA176745 and P01 CA066996 awarded by the National Institutes of Health. The government has certain rights in the invention.FIELD OF THE INVENTION[0003]This invention is in the area of improved compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse infla...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/11A61K35/17C07K16/00A61K31/4525A61K31/4545A61K31/4985A61K31/506A61K31/519A61K31/551A61K31/575C07K14/725C07K14/705C07K16/28A61K31/5513A61K31/58C07K14/47C12N15/90
CPCC12N15/11A61K2035/122C07K16/00A61K31/4525A61K31/4545A61K31/4985A61K31/506A61K31/519A61K31/551A61K31/575C07K14/7051C07K14/70517C07K14/70521C07K16/2863A61K31/5513A61K31/58C07K14/47C12N15/907C07K2317/622C07K2319/03C07K2319/20C07K2319/95A61K35/17C12N15/111C12N2310/20A61P35/00A61K39/4631A61K39/4611A61K39/464412A61K39/464406A61K48/00C12N2800/80
Inventor BRADNER, JAMESROBERTS, JUSTINNABET, BEHNAMWINTER, GEORGPHILLIPS, ANDREW J.HEFFERNAN, TIMOTHYBUCKLEY, DENNIS
Owner DANA FARBER CANCER INST INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com